/

Replimune

Develops oncolytic immunotherapies for cancer treatment.

BiotechnologyPharmaceuticals replimune.com ↗

Company facts

Founded: 2015
Employees: 479
Headquarters: United States
Type: Public
Listed: NASDAQ: REPL